152 related articles for article (PubMed ID: 18388964)
1. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Galanis E; Carlson SK; Foster NR; Lowe V; Quevedo F; McWilliams RR; Grothey A; Jatoi A; Alberts SR; Rubin J
Mol Ther; 2008 May; 16(5):979-84. PubMed ID: 18388964
[TBL] [Abstract][Full Text] [Related]
2. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2004 Jan; 24(1):177-85. PubMed ID: 14654955
[TBL] [Abstract][Full Text] [Related]
3. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Chawla SP; Chua VS; Fernandez L; Quon D; Blackwelder WC; Gordon EM; Hall FL
Mol Ther; 2010 Feb; 18(2):435-41. PubMed ID: 19826403
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.
Chawla SP; Chua VS; Fernandez L; Quon D; Saralou A; Blackwelder WC; Hall FL; Gordon EM
Mol Ther; 2009 Sep; 17(9):1651-7. PubMed ID: 19532136
[TBL] [Abstract][Full Text] [Related]
5. Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M
Curr Opin Mol Ther; 2005 Apr; 7(2):164-9. PubMed ID: 15844625
[TBL] [Abstract][Full Text] [Related]
6. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.
Chawla SP; Bruckner H; Morse MA; Assudani N; Hall FL; Gordon EM
Mol Ther Oncolytics; 2019 Mar; 12():56-67. PubMed ID: 30705966
[TBL] [Abstract][Full Text] [Related]
7. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM; Liu PX; Chen ZH; Liu L; Whitley MD; Gee C; Groshen S; Hinton DR; Beart RW; Hall FL
Cancer Res; 2000 Jul; 60(13):3343-7. PubMed ID: 10910035
[TBL] [Abstract][Full Text] [Related]
9. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience.
Gordon EM; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Bruckner HW; Hall FL
Int J Oncol; 2006 Nov; 29(5):1053-64. PubMed ID: 17016635
[TBL] [Abstract][Full Text] [Related]
10. Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
Hall FL; Levy JP; Reed RA; Petchpud WN; Chua VS; Chawla SP; Gordon EM
Oncol Rep; 2010 Oct; 24(4):829-33. PubMed ID: 20811660
[TBL] [Abstract][Full Text] [Related]
11. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent.
Gordon EM; Hall FL
Int J Oncol; 2010 Jun; 36(6):1341-53. PubMed ID: 20428757
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice.
Gordon EM; Chen ZH; Liu L; Whitley M; Liu L; Wei D; Groshen S; Hinton DR; Anderson WF; Beart RW; Hall FL
Hum Gene Ther; 2001 Jan; 12(2):193-204. PubMed ID: 11177556
[TBL] [Abstract][Full Text] [Related]
13. Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.
Ziske C; Nagaraj S; Märten A; Gorschlüter M; Strehl J; Sauerbruch T; Abraham NG; Schmidt-Wolf IG
J Interferon Cytokine Res; 2004 Aug; 24(8):490-6. PubMed ID: 15320962
[TBL] [Abstract][Full Text] [Related]
14. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice.
Chen DS; Zhu NL; Hung G; Skotzko MJ; Hinton DR; Tolo V; Hall FL; Anderson WF; Gordon EM
Hum Gene Ther; 1997 Sep; 8(14):1667-74. PubMed ID: 9322869
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Ikeda M; Sato A; Mochizuki N; Toyosaki K; Miyoshi C; Fujioka R; Mitsunaga S; Ohno I; Hashimoto Y; Takahashi H; Hasegawa H; Nomura S; Takahashi R; Yomoda S; Tsuchihara K; Kishino S; Esumi H
Cancer Sci; 2016 Dec; 107(12):1818-1824. PubMed ID: 27685612
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring.
Song JC; McDonnell PJ; Gordon EM; Hall FL; Anderson WF
Hum Gene Ther; 2003 Feb; 14(3):306-9. PubMed ID: 12675032
[No Abstract] [Full Text] [Related]
18. Rexin-G, a targeted genetic medicine for cancer.
Gordon EM; Hall FL
Expert Opin Biol Ther; 2010 May; 10(5):819-32. PubMed ID: 20384524
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Mahadevan D; Chalasani P; Rensvold D; Kurtin S; Pretzinger C; Jolivet J; Ramanathan RK; Von Hoff DD; Weiss GJ
Am J Clin Oncol; 2013 Jun; 36(3):239-43. PubMed ID: 22441342
[TBL] [Abstract][Full Text] [Related]
20. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct.
Xu F; Prescott MF; Liu PX; Chen ZH; Liau G; Gordon EM; Hall FL
Int J Mol Med; 2001 Jul; 8(1):19-30. PubMed ID: 11408944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
